The price-to-earnings ratio for Moderna Inc. (NASDAQ: MRNA) is above average at 7.60x. The 36-month beta value for MRNA is also noteworthy at 1.71. There are mixed opinions on the stock, with 9 analysts rating it as a “buy,” 3 rating it as “overweight,” 8 rating it as “hold,” and 1 rating it as “sell.”
The average price estimated by analysts for MRNA is $224.00, which is $74.05 above than the current price. The public float for MRNA is 346.94M, and at present, short sellers hold a 4.52% of that float. The average trading volume of MRNA on March 17, 2023 was 4.09M shares.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Sponsored
MRNA) stock’s latest price update
Moderna Inc. (NASDAQ: MRNA)’s stock price has decreased by -0.88 compared to its previous closing price of 151.78. Nevertheless, the company has seen a 8.79% surge in its stock price over the last five trading sessions.
MRNA’s Market Performance
MRNA’s stock has risen by 8.79% in the past week, with a monthly drop of -15.14% and a quarterly drop of -28.00%. The volatility ratio for the week is 4.52% while the volatility levels for the last 30 days are 4.03% for Moderna Inc. The simple moving average for the last 20 days is 2.30% for MRNA stock, with a simple moving average of -4.76% for the last 200 days.
Analysts’ Opinion of MRNA
Many brokerage firms have already submitted their reports for MRNA stocks, with TD Cowen repeating the rating for MRNA by listing it as a “Outperform.” The predicted price for MRNA in the upcoming period, according to TD Cowen is $180 based on the research report published on March 13th of the current year 2023.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see MRNA reach a price target of $200. The rating they have provided for MRNA stocks is “Outperform” according to the report published on March 02nd, 2023.
SVB Securities gave a rating of “Underperform” to MRNA, setting the target price at $93 in the report published on February 24th of the current year.
MRNA Trading at -10.44% from the 50-Day Moving Average
After a stumble in the market that brought MRNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -30.75% of loss for the given period.
Volatility was left at 4.03%, however, over the last 30 days, the volatility rate increased by 4.52%, as shares sank -13.13% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -15.60% lower at present.
During the last 5 trading sessions, MRNA rose by +8.24%, which changed the moving average for the period of 200-days by +3.00% in comparison to the 20-day moving average, which settled at $145.93. In addition, Moderna Inc. saw -16.24% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MRNA starting from Bancel Stephane, who sale 40,000 shares at the price of $139.20 back on Mar 09. After this action, Bancel Stephane now owns 5,411,946 shares of Moderna Inc., valued at $5,567,859 using the latest closing price.
Bancel Stephane, the Chief Executive Officer of Moderna Inc., sale 40,000 shares at $141.38 during a trade that took place back on Mar 08, which means that Bancel Stephane is holding 5,411,946 shares at $5,655,310 based on the most recent closing price.
Stock Fundamentals for MRNA
Current profitability levels for the company are sitting at:
- +48.49 for the present operating margin
- +69.84 for the gross margin
The net margin for Moderna Inc. stands at +43.76. Equity return is now at value 46.30, with 31.70 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 2.73.
Conclusion
In summary, Moderna Inc. (MRNA) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
